Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
ConclusionsAfter 13 days of treatment, imigliptin and alogliptin could decrease glycemic levels by improving beta-cell function. By comparing OMM with HOMA or SUIT results, glucose stimulation might be more sensitive for detecting changes in beta-cell function.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: China Health | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insulin | Statistics | Study | Transplants